HQY250117P100000
- 0.08
- 0.000.00%
HealthEquity Newsroom
JMP Securities Maintains HealthEquity(HQY.US) With Buy Rating, Raises Target Price to $120
BofA Securities Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $120
Wells Fargo Downgrades HealthEquity(HQY.US) to Hold Rating, Maintains Target Price $110
HealthEquity: Strong Growth Trajectory and Strategic Positioning Drive Buy Rating
RBC Capital Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $105
RBC Capital Sticks to Its Buy Rating for Healthequity (HQY)
Healthequity's Strong Performance and Promising Outlook Justifies Buy Rating
BofA Securities Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $120
BofA Securities Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $120
Barrington Maintains HealthEquity(HQY.US) With Buy Rating, Cuts Target Price to $112
Barrington Research Cuts HealthEquity Price Target to $112 From $120, Maintains Outperform Rating
HealthEquity Is Maintained at Outperform by RBC Capital
HealthEquity Price Target Raised to $105.00/Share From $100.00 by RBC Capital
HealthEquity Analyst Ratings
BTIG Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $130
Jefferies Maintains HealthEquity(HQY.US) With Buy Rating, Maintains Target Price $118
A Quick Look at Today's Ratings for HealthEquity(HQY.US), With a Forecast Between $105 to $130
Healthequity's Strong Financial Performance and Growth Prospects Support Buy Rating With $130 Price Target
JMP Securities Remains a Buy on Healthequity (HQY)
Mizuho Initiates Coverage On HealthEquity With Outperform Rating, Announces Price Target of $126